Chronic skin itching is not always related to an allergy or dry skin. When itching persists without an identifiable external cause, one avenue remains underexplored by both patients and some practitioners: the dysregulation of the immune system directed against the body’s own tissues. Several autoimmune diseases directly or indirectly cause skin itching, depending on distinct mechanisms that influence the choice of treatment.
Chronic autoimmune urticaria: when itching arises without an allergen
Most pages dedicated to itching classify urticaria among allergic reactions. This interpretation is incomplete. A form of chronic urticaria, known as autoallergic, results from the production of autoantibodies directed against IgE or its FcεRI receptor located on skin mast cells.
These autoantibodies activate mast cells without any external allergen being involved. The massive release of histamine that follows triggers persistent itching, often resistant to standard antihistamines. This condition lies exactly at the interface between allergy and autoimmunity, complicating its diagnosis.
A patient consulting for recurrent itching without an obvious allergic cause may wander for several months among different specialists. Identifying the mechanisms linking autoimmune disease and skin itching accelerates management, as the requested biological assessment (search for autoantibodies, tryptase levels) differs radically from that of a classic allergy.
Atopic dermatitis and psoriasis: two immune dysregulations, two types of itching
Atopic eczema and psoriasis are among the most common causes of chronic itching. Both involve a dysfunction of the skin immune system, but through distinct pathways.
Atopic dermatitis and Th2 imbalance
In atopic dermatitis, an overactivity of the Th2 immune response leads to chronic skin inflammation. This inflammation alters the skin barrier, partly due to a deficiency in filaggrin, a structural protein of the epidermis. The skin loses its protective function, becomes dry, and becomes permeable to irritants, which amplifies itching.
The cycle is self-perpetuating: itching causes scratching, which further damages the barrier, restarting inflammation. Without targeted intervention on the immune component, emollients alone are insufficient to break this cycle.
Psoriasis and accelerated cell turnover
Psoriasis operates through a different mechanism. The immune system attacks skin cells and accelerates their turnover, forming thick, scaly plaques. Itching affects the majority of psoriasis patients, although its intensity varies. It is often underestimated, as psoriasis remains associated in the public’s mind with an aesthetic issue rather than a systemic disease.
These two pathologies illustrate a key point: the same symptom (itching) can cover opposing immune mechanisms, making self-medication risky.
Lupus, dermatomyositis, scleroderma: systemic diseases with skin involvement
So-called non-organ-specific autoimmune diseases can also cause itching, sometimes as the first visible sign.
- Lupus erythematosus frequently manifests with photosensitive skin rashes (face, décolletage), accompanied by moderate to intense itching. These skin lesions may precede renal or joint involvement.
- Dermatomyositis combines muscle weakness with characteristic pruritic rashes around the eyes, on the hands, and elbows. Itching may be the initial reason for consultation before muscle involvement is identified.
- Scleroderma causes thickening and hardening of the skin, generating pulling sensations and itching related to progressive skin fibrosis.
In these systemic pathologies, itching is not just a minor inconvenience: it is a warning signal that can guide diagnosis. Chronic itching accompanied by fatigue, joint pain, or photosensitivity justifies an autoimmune assessment (antinuclear antibodies, native DNA, complement).
Treatments for autoimmune itching: what works and what remains limited
Treating itching related to an autoimmune disease is not limited to antihistamines. It depends on the underlying mechanism.
For chronic autoallergic urticaria, high-dose antihistamines are the first line of treatment. When they fail, treatments targeting mast cells or IgE (biotherapies) are considered. The available data does not yet allow predicting which patients will respond best to these treatments, and field reports vary on the duration of remission achieved.
For severe atopic dermatitis, recent immunomodulatory treatments specifically target the Th2 pathway. They significantly reduce inflammation and itching in some patients. Topical corticosteroids remain used for local treatment of flare-ups.
For psoriasis, anti-TNF, anti-IL-17, or anti-IL-23 biotherapies have transformed the management of moderate to severe forms. Itching generally decreases with the control of systemic inflammation, but some patients retain residual itching despite the disappearance of plaques.
For systemic diseases (lupus, dermatomyositis), treating itching involves controlling the underlying disease: immunosuppressants, corticosteroids, hydroxychloroquine as appropriate. Local care (emollients, topical corticosteroids) provides additional relief without treating the cause.
Consulting a doctor for chronic itching: what signals to monitor
An isolated itch lasting a few days rarely indicates an autoimmune cause. However, certain symptom combinations should prompt immediate consultation:
- Persistent itching for more than six weeks without an obvious dermatological cause
- Itching accompanied by unusual fatigue, joint pain, or weight loss
- Skin rashes triggered or worsened by sun exposure
- Family history of autoimmune diseases (genetic background increases susceptibility)
The primary care physician can refer to a dermatologist or internist based on the clinical picture. The initial blood work generally includes a search for autoantibodies, a complete blood count, and inflammatory markers. This simple assessment often suffices to rule out or confirm an autoimmune pathway.
Chronic itching remains a symptom that many patients trivialize or treat with self-medication. When itching resists usual treatments and is accompanied by general signs, the autoimmune pathway deserves early exploration, before the involvement of other organs complicates management.